CN105327337A - 抗辐射防龋消炎口腔制剂 - Google Patents
抗辐射防龋消炎口腔制剂 Download PDFInfo
- Publication number
- CN105327337A CN105327337A CN201510717026.2A CN201510717026A CN105327337A CN 105327337 A CN105327337 A CN 105327337A CN 201510717026 A CN201510717026 A CN 201510717026A CN 105327337 A CN105327337 A CN 105327337A
- Authority
- CN
- China
- Prior art keywords
- oral preparation
- radioprotective
- tinidazole
- oltipraz
- decayed tooth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 206010061218 Inflammation Diseases 0.000 title abstract description 7
- 230000003471 anti-radiation Effects 0.000 title abstract description 7
- 230000000675 anti-caries Effects 0.000 title abstract 5
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims abstract description 54
- CKNAQFVBEHDJQV-UHFFFAOYSA-N oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 claims abstract description 31
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960005053 tinidazole Drugs 0.000 claims abstract description 29
- 229950008687 oltipraz Drugs 0.000 claims abstract description 28
- 239000005844 Thymol Substances 0.000 claims abstract description 26
- 230000010261 cell growth Effects 0.000 claims abstract description 26
- 229960000790 thymol Drugs 0.000 claims abstract description 26
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 16
- 239000007921 spray Substances 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 239000004014 plasticizer Substances 0.000 claims abstract description 5
- 239000003381 stabilizer Substances 0.000 claims abstract description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 29
- 230000004223 radioprotective effect Effects 0.000 claims description 26
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 25
- 229960003742 phenol Drugs 0.000 claims description 25
- 241000209094 Oryza Species 0.000 claims description 24
- 235000007164 Oryza sativa Nutrition 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- 235000009566 rice Nutrition 0.000 claims description 24
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000005202 decontamination Methods 0.000 claims description 15
- 230000003588 decontaminative effect Effects 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 239000012153 distilled water Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 239000011521 glass Substances 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 235000013379 molasses Nutrition 0.000 claims description 8
- 239000008240 homogeneous mixture Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- 229920003081 Povidone K 30 Polymers 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 235000010980 cellulose Nutrition 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 229920003023 plastic Polymers 0.000 claims description 6
- 239000004033 plastic Substances 0.000 claims description 6
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 4
- 235000013339 cereals Nutrition 0.000 claims description 4
- -1 freshener Substances 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000003595 mist Substances 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000003507 refrigerant Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 7
- 208000025157 Oral disease Diseases 0.000 abstract description 6
- 208000030194 mouth disease Diseases 0.000 abstract description 6
- 238000011282 treatment Methods 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- 229940051866 mouthwash Drugs 0.000 abstract description 2
- 239000008183 oral pharmaceutical preparation Substances 0.000 abstract 2
- 230000000249 desinfective effect Effects 0.000 abstract 1
- YXUPZGKORWTXID-UHFFFAOYSA-N domiphen Chemical compound CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 YXUPZGKORWTXID-UHFFFAOYSA-N 0.000 abstract 1
- 229960000629 domiphen Drugs 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 239000002324 mouth wash Substances 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- 230000005855 radiation Effects 0.000 description 23
- 210000000214 mouth Anatomy 0.000 description 20
- 230000006378 damage Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 210000004877 mucosa Anatomy 0.000 description 9
- 208000002925 dental caries Diseases 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 206010025482 malaise Diseases 0.000 description 6
- 206010028116 Mucosal inflammation Diseases 0.000 description 5
- 201000010927 Mucositis Diseases 0.000 description 5
- 210000003298 dental enamel Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000005946 Xerostomia Diseases 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 206010013781 dry mouth Diseases 0.000 description 4
- 230000005865 ionizing radiation Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 208000003265 stomatitis Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000007565 gingivitis Diseases 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 2
- 208000005232 Glossitis Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- LAOOXBLMIJHMFO-UHFFFAOYSA-N 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one;hydron;chloride Chemical compound Cl.S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC LAOOXBLMIJHMFO-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- LBUIGEGXCYPINP-UHFFFAOYSA-N C(C)S(=O)(=O)CCN1C=NC=C1[N+](=O)[O-].CC1=C(C(=O)O)C=CC=C1C(=O)O Chemical class C(C)S(=O)(=O)CCN1C=NC=C1[N+](=O)[O-].CC1=C(C(=O)O)C=CC=C1C(=O)O LBUIGEGXCYPINP-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067418 Oral mucosal erythema Diseases 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 208000009019 Pericoronitis Diseases 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 241001464837 Viridiplantae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 231100000987 absorbed dose Toxicity 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000007691 actinomycosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940072359 anaprox Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000008971 epithelial apoptosis Effects 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000004966 intestinal stem cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 230000003537 radioprotector Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000001843 schistosomicidal effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明属于口腔药物制剂技术领域,特别涉及一种多功能抗辐射防龋消炎的口腔药物制剂。其技术方案是:一种抗辐射防龋消炎口腔制剂,它包括按质量分数计,0.5%~5%的奥替普拉、0.3%~2%的重组人角质细胞生长因子、0.02%~0.2%的度米酚、0.02%~0.2%的百里酚,0.02%~0.5%的替硝唑;余量为助药物、清新剂、甜味剂、增塑剂、崩解剂、清凉剂、稳定剂等;可制成漱口水、浓缩喷雾液,速崩洗消片三种不同剂型。本发明针对电离辐射性口腔疾病的致病因素研发,满足具有携带方便、平时预防保障和战时应急救治等多方面需求。
Description
技术领域
本发明属于口腔药物制剂技术领域,特别涉及一种多功能抗辐射防龋消炎的口腔药物制剂。
背景技术
人体在受到一定剂量的电离辐射作用后不仅在受照射当时可以出现早期急性效应,而且在受照若干年后甚至更长时间才出现远期效应。电离辐射对人体细胞内的水分子及生物分子如蛋白质的作用有特别重要的意义,其中水分子的电离和激发(ionizationandexcitation)产生自由基,而自由基是引起有机分子的放射损伤的主要原因;另外电离辐射可引起细胞分裂延迟(divisiondelay)改变及细胞死亡。由辐射产生的生物效应包括直接作用(directaction)和间接作用(indirectaction)。直接作用是辐射线自身或其生成的二次粒子直接作用于分子所造成的效应。例如用X射线照射生物体,将能量转给某个二次电子后,此电子再造成靶分子的游离,产生活性的游离基(freeradical),该游离基化学性质很活泼,结合至生物体内氢原子以外的原子,即可能造成所结合分子的变性,进而产生生物效应。间接作用是辐射线自身或由其生成的二次粒子,先作用于介质分子(例如水分子)上,使之成为化学性质活泼的产物(例如自由基、过氧化氢、水合电子等),此产物再继续作用于分子形成的效应。间接作用可受辐射敏感剂(radiosensitizer)或辐射保护剂(radioprotector)增强或减弱,直接作用则不易改变。引起的细胞损伤分3类:(1)致死性损伤(lethaldamage)不可逆的导致细胞死亡;(2)亚致死性损伤(sublethaldamage)正常情况下几小时内修复;(3)潜在致死性损伤(potentiallylethaldamage),在一定条件下损伤可修复。电离辐射队细胞损伤后的修复可分3个水平:(1)组织水平修复,即未受损的细胞在组织中再植;(2)细胞水平修复,即由于改变照射后细胞的环境条件或分割,细胞的存活增高;(3)分子水平的修复,即通过细胞内酶系的作用使受损伤的DNA分子恢复完整。
引起放射性黏膜损伤的主要射线是X线、β线及γ线。X、β线穿透能力强,除黏膜外,黏膜下组织、腺体,甚至骨骼也受损,有时产生溃疡长期不愈。β线损伤浅,治疗容易,只要处理得当,预后多数较好。此外,产生相同黏膜损伤所需的吸收剂量不同。γ线损伤黏膜吸收剂量较大,β线则较小。因为γ线的穿透能力强,电离作用小,传给黏膜的能量也小,部分能量消耗在深层组织。而β线的电离作用强,黏膜吸收的能量也多。有相当一部分X或γ线黏膜损伤合并有放射性病,使观察和治疗更为困难。慢性放射性黏膜损伤的临床表现:有较长的潜伏期,病情有明显的潜在性、进行性、反复性和持续性等特点。放射性口腔黏膜炎初始为口腔粘膜红肿,随后出现毛细血管反应性扩张,局部充血、红斑、糜烂、溃疡、假膜覆盖,严重者合并粘膜广泛萎缩和局部感染。常感口腔粘膜不适、口干、口臭,甚至持续难忍的疼痛感。放射线除直接损伤口腔黏膜外,并使放射野内的微血管发生肿胀,管壁增厚,管腔变窄或闭塞,出现受损部位供血不足,发生口腔黏膜炎。口干症是以腮腺为主的涎腺长期受照后出现腺泡和导管损伤,导致分泌量减少,随之唾液成分改变,口腔环境发生变化以及菌群失调。口腔内环境变化使得对细菌防御能力降低,变形链球菌和乳酸菌等细菌繁殖导致龋齿发生,甚至出现大面积急性放射性龋齿。同时受辐射后的正常牙齿牙颈部釉质出现脱矿现象,釉质灶性微孔增多、加深及釉质裂隙的出现,使口腔中的细菌和酸性物质沿釉质缺损进入釉质内部,并且抗酸性下降,加速龋损的发展进程,导致猖獗龋。目前临床处理的总体原则是预防为主,减轻症状、促进愈合、防治合并感染。对于放射性口腔黏膜炎临床上多采用局部消炎、杀菌和止痛剂来治疗和缓解,但是单纯的抗菌消炎对粘膜的修复起不到积极的作用,而辐射引起机体免疫力降低,常因合并其他感染而加重症状,影响创面愈合。
据第四军医大学口腔医学院对普通人群口腔流行病调查结果显示龋齿发病率为38.6%,牙龈炎牙周病发病率为59%,口腔黏膜炎发病率为4.7%,而口腔咽喉炎、口干症发病率几乎为0。而同期据对某工作单位500余名相关工作人员口腔流行病学、分子流行病学的临床现况调查结果显示:放射性龋齿发病率为97.4%,牙龈炎牙周病发病率为82%,放射性口腔黏膜炎发病率达53.6%,放射性口腔咽喉炎为27%,放射性口干症发病率高达87%。通过统计数据,可以看出相关工作人员龋病、口腔黏膜炎等口腔疾病高发,部分疾病发病率甚至比普通人群平均发病率高几十倍。分析致病因素主要有长期处于直接或间接电离辐射照射条件下,环境封闭、偏僻,基层医疗条件有限,口腔疾病常常合并有白色念珠菌、单纯疱疹病毒、厌氧菌等真菌、细菌和病毒的继发感染。同时辐射严重损害全身机体功能,,导致机体免疫、防御修复机能严重下降,使得病程迁延,反复发作。给相关工作人员带来极大的身心痛苦,严重影响他们日常工作及应急工作。据前期临床现况调查统计评估出勤率下降约20%-30%。
目前针对辐射性口腔疾病的药物一般是对症治疗,疗效欠佳,有一定的毒副作用,缺乏针对性和便携性,不适合用于应急保障、野外训练条件下的预防治疗。
发明内容
本发明的目的是:提供一种针对放射性口腔疾病、无毒副作用,且便携的多功能抗辐射防龋消炎口腔制剂、不同剂型及其制备方法。
本发明的技术方案是:一种抗辐射防龋消炎口腔制剂,包括奥替普拉、重组人角质细胞生长因子、度米酚、百里酚和替硝唑。
具体地,上述抗辐射防龋消炎口腔制剂中,所述组分按质量分数计,奥替普拉为0.5%~5%、重组人角质细胞生长因子为0.3%~2%、度米酚为0.02%~0.2%、百里酚为0.02%~0.2%,替硝唑0.02%~0.5%。
更具体地,上述抗辐射防龋消炎口腔制剂还包括清新剂、甜味剂、增塑剂、崩解剂、清凉剂、稳定剂;所述清新剂为食用香精;所述甜味剂选自以下一种或几种物质:糖蜜素、二肽甜味剂、阿斯巴甜;所述增塑剂选自以下一种或几种多元醇:甘油、山梨醇、乙醇、丙二醇和甘露醇;所述崩解剂选自以下一种或几种物质:交联羧甲基纤维素钠,羧甲基淀粉钠,联聚维酮;所述清凉剂选自以下一种或几种物质:薄荷油,薄荷脑,清凉醇;所述稳定剂选自可溶性淀粉和/或氨基酸。
再具体地,本发明提供了剂型为漱口水的抗辐射防龋消炎口腔制剂,它包括以质量分数计,0.5%的奥替普拉,0.3%的重组人角质细胞生长因子,0.02%的度米酚,0.02%的百里酚,0.02%的替硝唑,0.1%的糖蜜素,0.05%的薄荷脑,0.01%的薄荷油,2%的甘油,4%的乙醇,余量为蒸馏水;同时提供了所述漱口水的制备方法:在无菌生产车间中,将奥替普拉、重组人角质细胞生长因子、度米酚、百里酚、替硝唑按上述质量分数依次加入洁净的玻璃容器中,轻轻搅拌,充分混合均匀后,再加入上述质量分数的薄荷脑、薄荷油、甜味剂、甘油、乙醇、蒸馏水均匀混合物,将所有混合物充分混匀后,检测合格后灌装于灭菌塑料瓶中密封入库,室温保存。
本发明也提供了剂型为浓缩喷雾液的抗辐射防龋消炎口腔制剂,它包括以质量分数计,1.2%的奥替普拉,0.8%的重组人角质细胞生长因子,0.04%的度米酚,0.03%的百里酚,0.04%的替硝唑,0.1%的糖蜜素,0.05%的薄荷脑,0.01%的薄荷油,2%的甘油,4%的乙醇,余量为蒸馏水;同时提供了所述浓缩喷雾液的制备方法:在无菌生产车间中,将奥替普拉、重组人角质细胞生长因子、度米酚、百里酚、替硝唑,按上述质量分数依次加入洁净的玻璃容器中,轻轻搅拌,充分混合均匀后,再加入上述质量分数的薄荷脑、薄荷油、甜味剂、甘油、乙醇、蒸馏水均匀混合物,将所有混合物充分混匀后,输进储存罐,储存2小时,过滤、灌装50ml塑料喷雾瓶、封口、包装。
本发明还提供了剂型为速崩洗消片的抗辐射防龋消炎口腔制剂,它包括以质量分数计,5%的奥替普拉,2%的重组人角质细胞生长因子,0.2%的度米酚,0.2%的百里酚,0.5%的替硝唑,5%的可溶性淀粉,56.1%的甘露醇,9%的聚维酮K30,15%的微晶化纤维素,5%的交联聚维酮XL-10,2%的薄荷脑;同时提供了该速崩洗消片的制备方法:按所述质量分数分别称取奥替普拉、重组人角质细胞生长因子、度米酚、百里酚、替硝唑、甘露醇加入洁净的玻璃容器中,轻轻搅拌,充分混合均匀后,加入5%放入可溶性淀粉,组成速崩漱口片的活性成分单元,再加入9%的聚维酮K30溶液,搅拌,过40目筛制粒,干燥,将15%放入微晶化纤维素、5%的交联聚维酮XL-10、2%的薄荷脑分散于PROSOLVSMCC50(优化微晶纤维素50)中,与已制备的粒混匀,用13mm浅弧圆冲压片,片剂硬度控制在4kgf。
本发明主要活性成分及其功效如下:
奥替普拉:奥替普拉(Oltipraz,OLT),即5-(2-吡嗪基)-4-甲-1,2-二羟基-3-硫酮,是从十字花科蔬菜等绿色植物中提取的巯基化合物,最早用于血吸虫病的治疗。现有研究表明,放射照射前给予OLT,可以降低放射性舌炎的病情和缩短病程时间,预防效应与剂量相关,具有预防放射性口腔黏膜炎(radiation-inducedoralmucositis,ROM)的应用前景。奥替普拉对放射性舌炎的预防效应机制可能是通过保护保护RTG舌体病损组织内血管内皮细胞,减少血管内皮细胞脱落和调控炎症相关细胞因子。OLT是一种抗氧化剂,具有抗氧化、清自由基作用,结构与还原性谷胱甘肽相似,具有外源性化学物质的解毒、抗氧化剂的保护作用,与肿瘤的化学预防相关。1993年美国NCI倡仪用它作临床I期抗癌药物试验。
重组人角质细胞生长因子:重组人角质细胞生长因子(rhKGF)是具有肝素结合特性的成纤维细胞生长因子(FGF)家族中的一员,因此又称为FGF-7。近来研究表明,rhKGF具有广泛的生物学活性,尤其是其拮抗辐射损伤作用引人注目。rhKGF促进上皮细胞增殖与分化作用明显:rhKGF特异性的靶细胞是上皮细胞,外源性的KGF对皮肤创面的上皮细胞有促增殖作用,促进创面边缘上皮细胞增殖并移行覆盖创面,并且加速毛囊和皮脂腺祖干细胞的增殖和分化,从而促进创面的愈合。rhKGF在口腔黏膜组织疾病的发生发展过程中,rhKGF通过调节凋亡相关基因Bcl-2、Bax的表达来调节上皮细胞的凋亡程,从而在口腔黏膜病的发生及发展过程中发挥重要作用。rhKGF辐射防护作用较强。有研究表明,应用离体微集落测定法发现rhKGF可提高辐射后口腔黏膜细胞和肠干细胞的存活率,并能减轻辐射引起的胃肠毒性。通过测定荧光素异硫氰酸盐标记发现在同样剂量的辐照条件下rhKGF降低了培养单层细胞的通连性,说明rhKGF对辐射引起气道上皮细胞的通透性增高有拮抗作用,对通气道的屏障功能具有保护作用,对射线所诱发的肺损伤和辐射内照射气溶胶损伤也有较强防护作用。rhKGF对维持细胞骨架蛋白的主要成分F-肌纤蛋白的稳定和保护细胞-细胞间连结起重要作用。rhKGF结合受体相继激活PKC,阻止了F-肌纤蛋白的断裂并使胞内的G-肌纤蛋白向F-肌纤蛋白转变,保持了细胞结构的完整性。同时rhKGF通过促进细胞内的粘附分子表达,使细胞通过整合素粘住细胞内基质,维持细胞结构的完整。
度米酚:别名杜美芬、消毒灵、溴化度粉芬。为白或微黄色片状结晶,能溶于水及醇。系阳离子型表面活性广谱杀菌剂,抗菌谱及抗菌活性与苯扎溴铵(新洁尔灭)相似。其作用在碱性中增强。用于预防和治疗口腔、咽喉感染如咽喉炎、扁桃体炎和粘膜皮肤消毒等。
百里酚:与香芹酚是同分异构体,由于被发现于百里香中而得名。有令人愉快的芳香气味百里,是我国《食品添加剂使用卫生标准》规定允许使用的食品香料。溶于乙醇等有机溶剂,微溶于水和甘油。是很强的防腐剂。杀菌作用麝香草酚的杀菌作用比苯酚强,且毒性低,对口腔咽喉粘膜有杀菌、杀真菌作用,对口腔龋齿有预防作用,用于口腔、咽喉的消毒杀菌、放射菌病等。
替硝唑:白色或淡黄色结晶或结晶性粉末,味微苦。在丙酮或氯仿中溶解,在水或乙醇中微溶。替硝唑与甲硝唑同属硝基咪唑类。对厌氧菌有良好活性。革兰阳性厌氧菌(消化球菌、消化链球菌、乳杆菌属),梭状芽胞杆菌属和难辨梭菌等对替硝唑均较敏感;替硝唑对脆弱类杆菌、梭杆菌属和费氏球菌属等革兰阴性厌氧菌的作用强于甲硝唑。其作用机制为抑制病原体DNA合成、并能快速进入细胞内。替硝唑主要用于预防和治疗牙周炎,冠周炎等口腔感染及手术创口、皮肤粘膜软组织的感染。
本发明不仅能有效清除人体内多余的自由基,可以阻断外源因素导致的辐射损伤,具有超强的抗辐射作用,而且促进口腔黏膜创面细胞RNA及DNA的复制和蛋白质的合成,提供组织再生与修复的基础,缩短创面愈合时间,消炎止痛防治口腔黏膜炎;同时还能高效杀灭变形链球菌等龋病致病菌,去除牙菌斑防龋固齿,阻断牙龈炎、牙周炎致病进程,保持口腔卫生、无异味,消除牙本质过敏,使用后具有持久抗菌效果,能够长时间附着在牙齿或口腔表面,形成保护膜,温柔呵护口腔,而且口感良好,对人体安全。
本发明的漱口水、浓缩喷雾液,速崩洗消片三种不同剂型,可以根据需要灵活使用:漱口水剂型用于针对外照射损伤和气溶胶损伤的预防性漱口;浓缩喷雾液用于辐射急慢性粘膜皮肤损伤的紧急治疗药品;速崩洗消片,携带方便,溶解迅速,短时间产生大量洗消溶液,配合淋浴车使用,用于进入辐射场所前后口鼻腔粘膜和全身皮肤的洗消。
本发明可配备在平时预防保健药箱或应急药箱中以便应对相关工作人员的放射性口腔疾病,同时还可以用便携式速崩洗消片稀释调制洗消液用于进入辐射场所前后口鼻腔粘膜和全身皮肤的洗消,适应平时保障和应急救治两种不同条件,满足预防和治疗保障工作需求,对保护相关工作人员的身体健康具有重要现实意义。
具体实施方式
主要原料及其来源:
奥替普拉;厂家:湖北巨胜科技有限公司;产地:湖北货号:TR75-6;规格:10∶1;有效成分:5-(2-吡嗪基)-4-甲-1,2-二羟基-3-硫酮。
重组人角质细胞生长因子;厂家:近岸蛋白质科技有限公司;产地:上海近岸;货号:C029;规格:10μg/50μg/1mg;有效成分:重组人表皮生长因子(rhKGF)。
度米酚。厂家:南京法姆化学厂;产地:南京;货号:T1162-7;规格:10g/瓶;有效成分:白色或微黄色片状结晶Domifene;
百里酚;厂家:沈阳市试剂三厂;产地:沈阳;货号:CAS89-83-8;规格:10g/瓶;有效成分:2-异丙基-5甲基苯酚。
替硝唑;厂家:武汉远城化工科技有限公司;产地:武汉;货号:CAS80-34-5;规格:5kg纸板桶;有效成分:2-甲基-1-[2-(乙基磺酰基)乙基]-5-硝基-1H咪唑。
实施例1:抗辐射防龋消炎口腔漱口液的组成、制备、及使用
漱口水剂型抗辐射防龋消炎口腔制剂,它包括以质量分数计,0.5%的奥替普拉,0.3%的重组人角质细胞生长因子,0.02%的度米酚,0.02%的百里酚,0.02%的替硝唑,0.1%的糖蜜素,0.05%的薄荷脑,0.01%的薄荷油,2%的甘油,4%的乙醇,余量为蒸馏水。
制备方法:在无菌生产车间中,将奥替普拉、重组人角质细胞生长因子、度米酚、百里酚、替硝唑按上述质量分数依次加入洁净的玻璃容器中,轻轻搅拌,充分混合均匀后,再加入上述质量分数的薄荷脑、薄荷油、甜味剂、甘油、乙醇、蒸馏水均匀混合物,将所有混合物充分混匀后,检测合格后灌装于灭菌塑料瓶中密封入库,室温保存。
产品性状:从外观上看均匀混合溶液,一般为白色;口味上,甜度适中,不带苦味,冰凉;细菌总数:<100个/L;大肠杆菌:<30个/L;致病菌:不得检出。
使用方法:上述漱口液的使用方法为直接开启后漱口,用量为1-3次/天,50ml/次,含漱3分钟。
实施例2:抗辐射防龋消炎口腔浓缩喷雾液的组成、制备、及使用
浓缩喷雾液型抗辐射防龋消炎口腔制剂,它包括以质量分数计,1.2%的奥替普拉,0.8%的重组人角质细胞生长因子,0.04%的度米酚,0.03%的百里酚,0.04%的替硝唑,0.1%的糖蜜素,0.05%的薄荷脑,0.01%的薄荷油,2%的甘油,4%的乙醇,余量为蒸馏水。
制备方法:在无菌生产车间中,将奥替普拉、重组人角质细胞生长因子、度米酚、百里酚、替硝唑,按上述质量分数依次加入洁净的玻璃容器中,轻轻搅拌,充分混合均匀后,再加入上述质量分数的薄荷脑、薄荷油、甜味剂、甘油、乙醇、蒸馏水均匀混合物,将所有混合物充分混匀后,输进储存罐,储存2小时,过滤、灌装50ml塑料喷雾瓶、封口、包装。
产品形状:从外观上看均匀混合悬浊溶液,一般为白色;口味上,甜度适中,不带苦味,冰凉;细菌总数:<100个/100ml;大肠杆菌:<30个/100ml;致病菌:不得检出。
使用方法:直接开启后喷于患处即可,用量为1-3次/天,1-2ml/次,疗程一般为3-20天,剂量和疗程都可根据实际情况遵医嘱调整。也可将其按5ml溶液:200ml清水兑成漱口水,含漱3分钟用于平时口腔保健。
实施例3:抗辐射防龋消炎速崩洗消片的组成、制备、及使用
速崩洗消片剂型抗辐射防龋消炎口腔制剂,它包括以质量分数计,5%的奥替普拉,2%的重组人角质细胞生长因子,0.2%的度米酚,0.2%的百里酚,0.5%的替硝唑,5%的可溶性淀粉,56.1%的甘露醇,9%的聚维酮K30,15%的微晶化纤维素,5%的交联聚维酮XL-10,2%的薄荷脑。
制备方法:按所述质量分数分别称取奥替普拉、重组人角质细胞生长因子、度米酚、百里酚、替硝唑、甘露醇加入洁净的玻璃容器中,轻轻搅拌,充分混合均匀后,加入5%放入可溶性淀粉,组成速崩漱口片的活性成分单元,再加入9%的聚维酮K30溶液,搅拌,过40目筛制粒,干燥,将15%放入微晶化纤维素、5%的交联聚维酮XL-10、2%的薄荷脑分散于PROSOLVSMCC50(优化微晶纤维素50)中,与已制备的粒混匀,用13mm浅弧圆冲压片,片剂硬度控制在4kgf。
产品性状:成品从外观上看均匀、有光泽,一般为白色;口味上,甜度适中,不带苦味,冰凉;细菌总数:<100个/Kg;大肠杆菌:<30个/Kg;致病菌:不得检出。
使用方法:将按1片:1000mL清水的比例,投放到水中在3分钟内完全分解,形成皮肤黏膜洗消液。单人用量为1-3次/片。集体使用时按人数以上剂量累加。本实施例中,所述速崩洗消片
实施例4:产品性能指标检测
本发明的漱口水、浓缩喷雾液及速崩洗消片,经检测,满足表1所示的指标要求:
表1口腔制剂指标要求
Claims (9)
1.一种抗辐射防龋消炎口腔制剂,其特征是:它包括奥替普拉、重组人角质细胞生长因子、度米酚、百里酚和替硝唑。
2.根据权利要求1所述的抗辐射防龋消炎口腔制剂,其特征是,所述口腔制剂中,按质量分数计,奥替普拉为0.5%~5%、重组人角质细胞生长因子为0.3%~2%、度米酚为0.02%~0.2%、百里酚为0.02%~0.2%,替硝唑0.02%~0.5%。
3.根据权利要求2所述的抗辐射防龋消炎口腔制剂,其特征是,它还包括清新剂、甜味剂、增塑剂、崩解剂、清凉剂、稳定剂;所述清新剂为食用香精;所述甜味剂选自以下一种或几种物质:糖蜜素、二肽甜味剂、阿斯巴甜;所述增塑剂选自以下一种或几种多元醇:甘油、山梨醇、乙醇、丙二醇和甘露醇;所述崩解剂选自以下一种或几种物质:交联羧甲基纤维素钠,羧甲基淀粉钠,联聚维酮;所述清凉剂选自以下一种或几种物质:薄荷油,薄荷脑,清凉醇;所述稳定剂选自可溶性淀粉和/或氨基酸。
4.根据权利要求3所述的抗辐射防龋消炎口腔制剂,其特征是,所述抗辐射防龋消炎口腔制剂为漱口水,它包括以质量分数计,0.5%的奥替普拉,0.3%的重组人角质细胞生长因子,0.02%的度米酚,0.02%的百里酚,0.02%的替硝唑,0.1%的糖蜜素,0.05%的薄荷脑,0.01%的薄荷油,2%的甘油,4%的乙醇,余量为蒸馏水。
5.根据权利要求3所述的抗辐射防龋消炎口腔制剂,其特征是,所述抗辐射防龋消炎口腔制剂为浓缩喷雾液,它包括以质量分数计,1.2%的奥替普拉,0.8%的重组人角质细胞生长因子,0.04%的度米酚,0.03%的百里酚,0.04%的替硝唑,0.1%的糖蜜素,0.05%的薄荷脑,0.01%的薄荷油,2%的甘油,4%的乙醇,余量为蒸馏水。
6.根据权利要求3所述的抗辐射防龋消炎口腔制剂,其特征是,所述抗辐射防龋消炎口腔制剂为速崩洗消片,它包括以质量分数计,5%的奥替普拉,2%的重组人角质细胞生长因子,0.2%的度米酚,0.2%的百里酚,0.5%的替硝唑,5%的可溶性淀粉,56.1%的甘露醇,9%的聚维酮K30,15%的微晶化纤维素,5%的交联聚维酮XL-10,2%的薄荷脑。
7.一种制备如权利要求4所述抗辐射防龋消炎口腔制剂的方法,其特征是,所述方法包括以下步骤:在无菌生产车间中,将奥替普拉、重组人角质细胞生长因子、度米酚、百里酚、替硝唑按权利要求4所述的质量分数依次加入洁净的玻璃容器中,轻轻搅拌,充分混合均匀后,再加入权利要求4所述质量分数的薄荷脑、薄荷油、甜味剂、甘油、乙醇、蒸馏水均匀混合物,将所有混合物充分混匀后,检测合格后灌装于灭菌塑料瓶中密封入库,室温保存。
8.一种制备如权利要求5所述抗辐射防龋消炎口腔制剂的方法,其特征是,所述方法包括以下步骤:在无菌生产车间中,将奥替普拉、重组人角质细胞生长因子、度米酚、百里酚、替硝唑,按权利要求5所述质量分数依次加入洁净的玻璃容器中,轻轻搅拌,充分混合均匀后,再加入权利要求5所述质量分数的薄荷脑、薄荷油、甜味剂、甘油、乙醇、蒸馏水均匀混合物,将所有混合物充分混匀后,输进储存罐,储存2小时,过滤、灌装50ml塑料喷雾瓶、封口、包装。
9.一种制备如权利要求6所述抗辐射防龋消炎口腔制剂的方法,其特征是,,所述方法包括以下步骤:按权利要求6所述质量分数分别称取奥替普拉、重组人角质细胞生长因子、度米酚、百里酚、替硝唑、甘露醇加入洁净的玻璃容器中,轻轻搅拌,充分混合均匀后,加入5%放入可溶性淀粉,组成速崩漱口片的活性成分单元,再加入9%的聚维酮K30溶液,搅拌,过40目筛制粒,干燥,将权利要求6所述的15%放入微晶化纤维素、5%的交联聚维酮XL-10、2%的薄荷脑分散于优化微晶纤维素50中,与已制备的粒混匀,用13mm浅弧圆冲压片,片剂硬度控制在4kgf。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510717026.2A CN105327337A (zh) | 2015-10-30 | 2015-10-30 | 抗辐射防龋消炎口腔制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510717026.2A CN105327337A (zh) | 2015-10-30 | 2015-10-30 | 抗辐射防龋消炎口腔制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105327337A true CN105327337A (zh) | 2016-02-17 |
Family
ID=55278242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510717026.2A Pending CN105327337A (zh) | 2015-10-30 | 2015-10-30 | 抗辐射防龋消炎口腔制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105327337A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020058767A1 (en) * | 2018-09-18 | 2020-03-26 | St Ip Holding Ag | Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2- dithiole-3-thiones |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009004168A2 (fr) * | 2007-05-31 | 2009-01-08 | Airbus France | Escalier pour aéronef |
| CN101411805A (zh) * | 2008-11-07 | 2009-04-22 | 湖南易科生物工程科技发展有限公司 | 纯天然抗辐射网络含片 |
| CN102639100A (zh) * | 2009-08-20 | 2012-08-15 | 托马斯·贝尔纳多·加尔万冈萨雷斯 | 用于口腔卫生和治疗微生物起源的口腔疾病的抗菌药物组合物 |
| CN104107379A (zh) * | 2014-07-03 | 2014-10-22 | 河南科技大学第一附属医院 | 一种牙齿止痛消炎片及其制备方法 |
| CN104491840A (zh) * | 2014-12-30 | 2015-04-08 | 中国人民解放军第四军医大学 | 一种抗辐射防龋消炎的口腔药物组合物及其制剂 |
-
2015
- 2015-10-30 CN CN201510717026.2A patent/CN105327337A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009004168A2 (fr) * | 2007-05-31 | 2009-01-08 | Airbus France | Escalier pour aéronef |
| CN101411805A (zh) * | 2008-11-07 | 2009-04-22 | 湖南易科生物工程科技发展有限公司 | 纯天然抗辐射网络含片 |
| CN102639100A (zh) * | 2009-08-20 | 2012-08-15 | 托马斯·贝尔纳多·加尔万冈萨雷斯 | 用于口腔卫生和治疗微生物起源的口腔疾病的抗菌药物组合物 |
| CN104107379A (zh) * | 2014-07-03 | 2014-10-22 | 河南科技大学第一附属医院 | 一种牙齿止痛消炎片及其制备方法 |
| CN104491840A (zh) * | 2014-12-30 | 2015-04-08 | 中国人民解放军第四军医大学 | 一种抗辐射防龋消炎的口腔药物组合物及其制剂 |
Non-Patent Citations (7)
| Title |
|---|
| 余德荣: "角质细胞生长因子对放化疗引起的口腔黏膜炎的防治作用", 《国际生物制品学杂志》 * |
| 吴军正等: "替硝唑口腔贴片治疗牙周炎的临床疗效及安全性", 《第四军医大学学报》 * |
| 孙华君主编: "《基层医生常用药物速查手册》", 31 October 2011, 金盾出版社 * |
| 宫新江等: "重组人角质细胞生长因子对放射性和放疗性口腔黏膜的防治作用", 《中国药理学与毒理学杂志》 * |
| 师海波等主编: "《临床最新药物手册》", 31 January 2013, 军事医学科学出版社 * |
| 李春阳: "奥替普拉对大鼠放射性舌炎的预防作用及其机制", 《中国学位论文全文数据库》 * |
| 李翔等主编: "《口腔临床药物学》", 31 May 2013, 郑州大学出版社 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020058767A1 (en) * | 2018-09-18 | 2020-03-26 | St Ip Holding Ag | Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2- dithiole-3-thiones |
| CN113694068A (zh) * | 2018-09-18 | 2021-11-26 | St知识产权控股公司 | 4-烷基-5-杂芳基-3h-1,2-二硫杂环戊烯-3-硫酮的旋转异构异构体 |
| JP2022501424A (ja) * | 2018-09-18 | 2022-01-06 | エスティー アイピー ホールディング エージー | 4−アルキル−5−ヘテロアリール−3h−1,2−ジチオール−3−チオンの回転異性体 |
| JP7514841B2 (ja) | 2018-09-18 | 2024-07-11 | エスティー アイピー ホールディング エージー | 4-アルキル-5-ヘテロアリール-3h-1,2-ジチオール-3-チオンの回転異性体 |
| US12312343B2 (en) | 2018-09-18 | 2025-05-27 | St Ip Holding Ag | Rotomeric isomers of 4-alkyl-5-heteroaryl-3H-1,2-dithiole-3-thiones |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Srikanth et al. | Application of ozone in the treatment of periodontal disease | |
| US9393249B2 (en) | Antimicrobial composition | |
| EP3603654A1 (en) | Prevention and treatment of microbial infections | |
| CN101199466B (zh) | 独一味药物牙膏及其制备工艺 | |
| CN102579702A (zh) | 一种治疗口腔溃疡的药物及其制备方法 | |
| TW201039835A (en) | Chlorine dioxide treatment for biological tissue | |
| Tayal et al. | Current perspectives on use of Aloe vera in dentistry. | |
| CN109223663A (zh) | 一种用于牙龈炎症的中草药牙膏及其制备方法 | |
| CN108042420B (zh) | 一种用于口腔保健的组合物及其应用 | |
| CN104491840B (zh) | 一种抗辐射防龋消炎的口腔药物组合物及其制剂 | |
| KR20060040603A (ko) | 아스코르브산을 포함하는 진균성 중복감염들 및 진균성재발들의 치료용 약학적 조성물들 | |
| RU2184538C2 (ru) | Применение дихлорбензилового спирта для получения лекарственного средства для местного лечения воспаления и лекарственное средство, содержащее дихлорбензиловый спирт | |
| CN106309483A (zh) | 一种牙髓消炎糊剂及其制备方法 | |
| CN105327337A (zh) | 抗辐射防龋消炎口腔制剂 | |
| CN109674875A (zh) | 口腔溃疡护理精华液 | |
| CN100448424C (zh) | 一种纳米氧化锌丁香油根管充填材料及其制备方法 | |
| RU2630612C1 (ru) | Фармацевтическая композиция для лечения и профилактики стоматологических заболеваний | |
| Riyanti et al. | Antibacterial Activity of Allium sativum against Streptococcus mutans ATCC 25175 in Indonesia. | |
| CN111345288A (zh) | 一种可以在呼吸防护器表面形成杀菌抗病毒涂层的胶性载体、胶性酊剂和应用 | |
| CN104324062A (zh) | 西洋参转化皂苷、其中药口腔护理组合物及制备方法和应用 | |
| Durgapal et al. | Effectiveness of Ozone against common dental problems: a literature review | |
| CN111632073A (zh) | 一种抗菌消炎的女性私密益生菌组合物及其制备 | |
| CN117137869A (zh) | 一种用于口腔粘膜保护及修复的凝胶喷雾剂、制备方法及其应用 | |
| CN103110609A (zh) | 一种治疗口腔溃疡的涂膜剂及其制备方法 | |
| Casu | Photodynamic therapy against multidrug-resistant oral strains of Candida spp |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160217 |
|
| WD01 | Invention patent application deemed withdrawn after publication |